

Publications

Yu, E & Erck, A & Aragon-Ching, JB. (2021). Advances in Systemic Therapy for Urothelial Cancer: Evolution of the Field. In HS Watanabe (Ed.), Horizons in Cancer Research, Volume 79 (pp. 131- 168). Nova Science Publishers, Inc. <https://novapublishers.com/shop/horizons-in-cancerresearch-volume-79/>

Yu EM, Kittai A, Tabbara I. Chronic Lymphocytic Leukemia: Current Concepts. Anticancer Res. 2015 Oct;35(10):5149-65.

Kittai A, **Yu EM**, Tabbara I. Granulocytic sarcoma in a patient with chronic myeloid leukaemia in complete haematological, cytogenetic and molecular remission. BMJ Case Reports. 2014 Dec 23; doi:10.1136/bcr-2014-207466.

Yu EM, Kittai A, Aragon-Ching JB. Leiomyosarcoma: Risk Factors, Diagnosis and Treatment Options. 1st ed. New York: Nova Science Publishers; c2014. Chapter 2, Leiomyosarcomas of the Genitourinary Tract; p. 75-90.

El-Ayass W, **Yu EM**, Karcher DS, Aragon-Ching JB. Complete response to EPOCH in a patient with HIV and extracavitary primary effusion lymphoma involving the colon: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2012 Apr;12(2):144-7.

Yu EM, Jain M, Aragon-Ching JB. Angiogenesis inhibitors in prostate cancer therapy. Discov Med. 2010 Dec;10(55):521-30.

Yu EM, El-Ayass W, Aragon-Ching JB. The use of 5-alpha reductase inhibitors for the prevention of prostate cancer. Cancer Biol Ther. 2010 Jul 13;10(1).

Yu, E.-m.; Linville, L.; Rosenthal, M.; Aragon-Ching, J.B. A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma. Vaccines 2021, 9, 919. <https://doi.org/10.3390/vaccines9080919>

Eun-mi Yu & Jeanny B. Aragon-Ching (2022) Advances with androgen deprivation therapy for prostate cancer, Expert Opinion on Pharmacotherapy, 23:9, 1015-1033, DOI: 10.1080/14656566.2022.2033210

Yu EM, Belay S, Li W, Aragon-Ching JB. Non-urothelial and urothelial variants of bladder cancer [published online ahead of print, 2022 Nov 20]. Cancer Treat Res Commun. 2022;33:100661. doi:10.1016/j.ctarc.2022.100661

Yu E, Mudireddy M, Biswas R, Aragon-Ching JB. The role of switch maintenance therapy in urothelial cancers. Therapeutic Advances in Urology. 2023;15. doi:10.1177/17562872221147760

Yu EM, Hwang MW, Aragon-Ching JB. Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities. Res Rep Urol. 2023;15:519-529. <https://doi.org/10.2147/RRU.S386517>.

Eun-mi Yu et al., Racial differences and predictors of outcomes in testicular cancer based on the National Cancer Database (NCDB).. JCO 42, 503-503(2024). DOI:10.1200/JCO.2024.42.4_suppl.503.

Eun-mi Yu et al., Metastatic testicular cancer (TC) presentations and outcomes: A contemporary analysis based on the National Cancer Database (NCDB).. JCO 42, e17016-e17016(2024).
DOI:10.1200/JCO.2024.42.16_suppl.e17016

Faran Polani, Min Woo Hwang, **Eun-mi Yu**, Hongkun Wang, and Jeanny B. Aragon-Ching., Analyzing disparities in socioeconomic factors, clinical characteristics, and outcomes in bladder cancer: Insights from the National Cancer Database (NCDB).. JCO 42, 4572-4572(2024).
DOI:10.1200/JCO.2024.42.16_suppl.4572

Aslanova M, **Yu EM**, Aragon-Ching JB. The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC). Explor Target Antitumor Ther. 2024;5:971–80. <https://doi.org/10.37349/etat.2024.00258>